



**Figure S1: Immunofluorescence staining prior to colony formation assay.** IF analysis prior to seeding of treated JEB keratinocytes onto feeder layer for colony formation analysis revealed a high C17 restoration efficiency for all gene editing strategies.




**Figure S2: Analysis of off-target indel formation and ssODN integration.** NGS-based analysis of previously identified off-target sites for sgRNA 3' (OT11) and sgRNA 5' (OT1 and OT3) revealed no signs of indel formation and ssODN integration.




**Figure S3: Western blot analysis of cell culture lysates**

Western blot analysis of cell culture lysates of RNP (w/wo ssODN)-treated primary JEB keratinocytes revealed the presence of full-length C17 at a size of 180 kDa.



**Figure S4: Western blot analysis of cell culture supernatants.** (A) Western blot analysis of supernatants of RNP (w/wo ssODN)-treated primary JEB keratinocytes and wild-type keratinocytes (hKc) revealed the presence of the C17 ectodomain at a size of 120 kDa. (B) Ponceau red staining of cell culture supernatants.



**Figure S5: Gating strategy for flow cytometric analysis of C17-stained JEB keratinocytes.**

	Forward primer (5' – 3')	Reverse primer (5' – 3')
PCR On-target	TAAGCCCGGTTTCCTTCCAC	TACGCTGCATGCTCTCTGAC
NGS On-target	TCGTCGGCAGCGTCAGATGTG TATAAGAGACAGCCCACTCAT GCAGCTTCTCACC	GTCTCGTGGGCTCGGAGATGTG TATAAGAGACAGCGATGTCAGT GCCATAGGGACC
NGS off-target 11 – sgRNA 3'	AAAACGGGAAAAGTCCCTCTC	GAGAGACTCACGCTGTCACG
NGS off-target 1 – sgRNA 5'	CATTGCCACGAGTATTGCAT	CCCTGGGAAAAGATGTGACT
NGS off-target 3 – sgRNA 5'	GAGTTACTGCCCTTTCCAT	CCACAAGGTTCTTGGCTTT
sqRT-PCR – <i>COL17A1</i>	GCAATGGCGGACTATTGGGA	AGTCACGTTGCTGTAGGCAG
sqRT-PCR – <i>GAPDH</i>	GCCAACGTGTCAGTGGTGGA	CACCACCCTGTTGCTGTAGCC
ssODN	C*A*C*GGATGCCTCCCACAGTCGGGGTAGCAGCTCCTCCTCACA CAGTCTATCTGTCAGGCGGGCAGCTCCTACAGCTCTTCCATGAG CACAGGAGGAG*G*T*	

\*Phosphorothioate backbone

**Table S1: Primers used for PCR, NGS on-and off-target PCR and sqRT-PCR.**

Treatment	relative clonal growth area [%]
Control	100,0
Electroporation	145,1
Cas9	126,6
ssODN	127,3
Cas9/sgRNA 3'	66,2
Cas9/sgRNA 3' + ssODN	52,6
Cas9n/sgRNA 5'+3'	35,8
Cas9n/sgRNA 5'+3' + ssODN	37,7

**Table S2: Relative clonal growth area upon CRISPR/Cas9 treatment**